News Mar 5, 2021

Jacobs Wins Mark Cuban Cost Plus Drug Company, PBC Contract to Deliver Pharmaceutical Facility

The flexible fill-finish facility will provide low-cost versions of high-cost generic drugs

Mark Cuban Cost Plus Drug Company

Jacobs was selected to provide Engineering services for Mark Cuban Cost Plus Drug Company, PBC’s facility in Dallas, Texas. The facility will provide low-cost versions of high-cost generic drugs. 

Mark Cuban Cost Plus Drug Company, PBC contracted Jacobs to complete facility design from concept through construction assistance. The 22,000-square-foot sterile fill-finish facility, to be registered with the U.S. Food and Drug Administration to allow ultimate flexibility for rapid response to drug shortages, will support the formulation, filling and packaging of sterile medicines. 

“We look forward to helping Mark Cuban Cost Plus Drug Company, PBC deliver on its aim to make essential life-enhancing drugs available to more people,” says Jacobs People & Places Solutions Executive Vice President, Ken Gilmartin."The facility’s innovative design will allow for the production of small product batches considered in short supply by the FDA  and those intended for treatment of rare diseases that typically affect a smaller population, known as orphan drugs”

The identification of mechanical enhancements and use of advancements in equipment have been key to reducing construction and capital costs. Supporting the delivery program of just over two years, Jacobs completed concept and finished detailed design within 12 months, compared to a typical timeframe of 20 to 24 months for sterile fill-facilities.

The pharmaceutical manufacturing facility is in Deep Ellum, one of the most historically and culturally significant neighborhoods in Dallas. As a nod to the area known for its  entertaining local music, enriching performances and art shows, the building’s final design includes paintable building panels which can be commissioned to a local artist when construction of the facility is complete in 2022.